The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach-Reference-Cited by-同舟云学术

The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach

Published:2014-04-02 Issue:2 Volume:166 Page:177-188
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Sivina Mariela¹,Kreitman Robert J.²,Arons Evgeny²,Ravandi Farhad¹,Burger Jan A.¹

Affiliation:

1. Department of Leukemia; M. D. Anderson Cancer Center; The University of Texas; Houston TX USA

2. Laboratory of Molecular Biology; National Cancer Institutes of Health; Bethesda MD USA

Funder

Cancer Prevention and Research Institute of Texas

CLL Global Research Foundation

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12867/fullpdf

Reference43 articles.

1. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies;Advani;Journal of Clinical Oncology,2013

2. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy;Arons;Blood,2009

3. Bruton tyrosine kinase inhibitor ibrutinib (PCI 32765);Burger;Leukemia & Lymphoma,2013

4. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment;Burger;Blood,2006

5. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling;Burger;Blood,2013

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group;Cancers;2024-06-10

2. Ibrutinib Modulates Proliferation, Migration, Mitochondrial Homeostasis, and Apoptosis in Melanoma Cells;Biomedicines;2024-05-04

3. Hairy cell leukemia 2024: Update on diagnosis, risk‐stratification, and treatment—Annual updates in hematological malignancies;American Journal of Hematology;2024-03-05

4. Hairy Cell Leukemia: Where Are We in 2023?;Current Oncology Reports;2023-04-25

5. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts;Blood;2023-03-30